<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2026-19-3-101-106</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-2232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FOR OPHTHALMOLOGY PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Применение обратимой электропорации при дисфункции мейбомиевых желез на фоне системной ретиноидной терапии. Клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>The use of reversible electroporation for meibomian gland dysfunction during systemic retinoid therapy. A case report</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4138-0495</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киселе</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kisele</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анастасия Сергеевна Киселе — врач-офтальмолог.</p><p>Мичуринский проспект, д. 56, стр. 1, Москва, 119192</p></bio><bio xml:lang="en"><p>Anastasia S. Kisele — ophthalmologist.</p><p>Michurinsky Prospekt, 56, Bldg. 1, Moscow, 119192</p></bio><email xlink:type="simple">kisele.as@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-3356-3152</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яворовская</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yavorovskaya</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александра Александровна Яворовская — врач-офтальмолог.</p><p>Ул. Солянка, д. 12, стр. 1, Москва, 109028</p></bio><bio xml:lang="en"><p>Alexandra A. Yavorovskaya — ophthalmologist.</p><p>12, Bldg. 1, Solyanka St., Moscow, 109028</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>АО «Группа компаний “МЕДСИ”», Многофункциональный медицинский центр на Мичуринском проспекте</institution><country>Россия</country></aff><aff xml:lang="en"><institution>JSC “MEDSI Group of Companies”, Multifunctional Medical Center on Michurinsky Prospekt</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>АО «Группа компаний “МЕДСИ”», Клинико-диагностический центр на Солянке</institution><country>Россия</country></aff><aff xml:lang="en"><institution>JSC “MEDSI Group of Companies”, Clinical and Diagnostic Center on Solyanka</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>28</day><month>09</month><year>2026</year></pub-date><volume>19</volume><issue>3</issue><fpage>101</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Киселе А.С., Яворовская А.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Киселе А.С., Яворовская А.А.</copyright-holder><copyright-holder xml:lang="en">Kisele A.S., Yavorovskaya A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/2232">https://roj.igb.ru/jour/article/view/2232</self-uri><abstract><p>Представлен клинический случай развития выраженной дисфункции мейбомиевых желез и синдрома сухого глаза у пациентки 28 лет, получавшей системную терапию изотретиноином по поводу акне. Стандартное лечение с использованием противовоспалительных и слезозаместительных препаратов, а также массажа век не дало удовлетворительных результатов. В связи с этим было принято решение о проведении обратимой электропорации с помощью высокочастотного генератора постоянного тока (аппарат Jett Medical OPH). Процедуру проводили курсом из трех сеансов с интервалом 7 дней. По итогам лечения зафиксировано существенное улучшение клинической картины: уменьшилась гиперемия и отечность век, повысилась подвижность секрета мейбомиевых желез, увеличились показатели времени разрыва слезной пленки и толщина ее липидного слоя, а также значительно сократились субъективные жалобы. Тест-опросник OSDI (Ocular Surface Disease Index) показал снижение баллов с 34 до 15, а частота применения увлажняющих капель уменьшилась с 20–30 до 2 раз в сутки. Заключение. Применение обратимой электропорации продемонстрировало высокую эффективность и безопасность, что делает ее перспективным методом выбора для пациентов с офтальмологическими осложнениями на фоне системной терапии ретиноидами, особенно в случаях, когда интенсивный импульсный свет противопоказан.</p></abstract><trans-abstract xml:lang="en"><p>The article presents a clinical case of a 28-year-old female patient undergoing systemic isotretinoin therapy for acne, who developed pronounced meibomian gland dysfunction and dry eye syndrome. Standard treatment with anti-inflammatory agents, tear substitutes, and eyelid massage failed to produce satisfactory results. Consequently, a decision was made to initiate reversible cold electroporation therapy using a high-frequency direct current generator on the Jett Medical OPH device. The procedure was performed as a course of three sessions spaced 7 days apart. Following treatment, significant clinical improvement was observed: eyelid hyperemia and edema decreased, meibomian secretion mobility improved, tear break-up time and lipid layer thickness increased, and the patient’s subjective symptoms markedly diminished. The Ocular Surface Disease Index (OSDI) score decreased from 34 to 15, and the frequency of tear substitute instillation was reduced from 20–30 times to 2 times per day. Conclusion. Application of reversible electroporation demonstrated high efficacy and safety, making it a promising treatment option for patients with ocular complications associated with systemic retinoid therapy, particularly in cases where intense pulsed light therapy is contraindicated.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>блефарит</kwd><kwd>синдром сухого глаза</kwd><kwd>дисфункция мейбомиевых желез</kwd><kwd>изотретиноин</kwd><kwd>неаблятивная обратимая электропорация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>blepharitis</kwd><kwd>dry eye syndrome</kwd><kwd>meibomian gland dysfunction</kwd><kwd>isotretinoin</kwd><kwd>non-ablative reversible electroporation</kwd><kwd>therapy</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">никто из авторов не имеет финансовой заинтересованности в представленных материалах или методах</funding-statement><funding-statement xml:lang="en">no author has a financial or property interest in any material or method mentioned</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Матушевская Е.В., Антонова Л.А., Матушевская Ю.И., Петрова К.С. Клинический опыт применения системного изотретиноина в лечении тяжелых форм акне. Русский медицинский журнал. 2018; 8 (II): 109–12.</mixed-citation><mixed-citation xml:lang="en">Matushevskaya E.V., Antonova L.A., Matushevskaya Yu.I, Petrova K.S. Clinical experience in the use of systemic isotretinoin in the treatment of severe forms of acne. Russian medical journal. 2018; 8 (II): 109–12 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Анисимова М.Ю. Угревая болезнь (Acne vulgaris) с позиции доказательной медицины. Вестник репродуктивного здоровья. 2010; (3–4): 14–23.</mixed-citation><mixed-citation xml:lang="en">Anisimova M.Yu. Acne (Acne vulgaris) from the perspective of evidence-based medicine. Bulletin of reproductive health. 2010; (3–4): 14–23 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Масюкова С.А., Мордовцева В.В., Кахишвили Н.Н. и др. Лечение акне низкими дозами изотретиноина. Клиническая дерматология и венерология. 2013; 11 (6): 7–12.</mixed-citation><mixed-citation xml:lang="en">Masjukova S.A., Mordovceva V.V., Kakhishvili N.N., et al. Low-dose isotretinoin treatment of acne. Klin dermatol venerol. 2013; 11 (6): 7–12 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Львов А.Н., Корнят М.С., Игошина А.В., Назаренко А.Р. Перспективы терапии акне: аналитический обзор. Клиническая дерматология и венерология. 2019; 18 (2): 115–28. doi: 10.17116/klinderma201918021115</mixed-citation><mixed-citation xml:lang="en">Lvov A.N., Kornyat M.S., Igoshina A.V., Nazarenko A.R. Perspectives in acne therapy: an analytical review. Klin dermatol venerol. 2019; 18 (2): 115–28 (In Russ.). doi: 10.17116/klinderma201918021115</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Oon HH, Wong SN, Aw DCW, et al. Acne management guidelines by the Dermatological Society of Singapore. J Clin Aesthet Dermatol. 2019; 12 (7): 34–50. PMID: 31531161.</mixed-citation><mixed-citation xml:lang="en">Oon HH, Wong SN, Aw DCW, et al. Acne management guidelines by the Dermatological Society of Singapore. J Clin Aesthet Dermatol. 2019; 12 (7): 34–50. PMID: 31531161.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Fallah H, Rademaker M. Isotretinoin for acne vulgaris: an update on adverse effects and laboratory monitoring. J Dermatolog Treat. 2022 Aug; 33 (5): 2414–24. doi: 10.1080/09546634.2021.1967269</mixed-citation><mixed-citation xml:lang="en">Fallah H, Rademaker M. Isotretinoin for acne vulgaris: an update on adverse effects and laboratory monitoring. J Dermatolog Treat. 2022 Aug; 33 (5): 2414–24. doi: 10.1080/09546634.2021.1967269</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bergler-Czop B, Brzezińska-Wcisło L, Słuczanowska-Głąbowska S, Safranow K, Machalińska A. Side effects of retinoid therapy on the quality of vision. Acta Pharm. 2016; 66 (4): 471–8. doi: 10.1515/acph-2016-0039</mixed-citation><mixed-citation xml:lang="en">Bergler-Czop B, Brzezińska-Wcisło L, Słuczanowska-Głąbowska S, Safranow K, Machalińska A. Side effects of retinoid therapy on the quality of vision. Acta Pharm. 2016; 66 (4): 471–8. doi: 10.1515/acph-2016-0039</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lamberg O, Strome A, Jones F, Mleczek J, Jarocki A, Troost JP, Helfrich Y. Ocular side effects of systemic isotretinoin – a systematic review and summary of case reports. J Dermatolog Treat. 2023; 34 (1): 2213364. doi: 10.1080/09546634.2023.2213364</mixed-citation><mixed-citation xml:lang="en">Lamberg O, Strome A, Jones F, Mleczek J, Jarocki A, Troost JP, Helfrich Y. Ocular side effects of systemic isotretinoin – a systematic review and summary of case reports. J Dermatolog Treat. 2023; 34 (1): 2213364. doi: 10.1080/09546634.2023.2213364</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Киселе А.С., Маслова Е.В., Трубилин А.В., Яворовская А.А., Чернуха В.А. Синдром сухого глаза, ассоциированный с дисфункцией мейбомиевых желез на фоне применения изотретиноина: клинический случай. The EYE ГЛАЗ. 2024; 26 (4): 264–72. doi: 10.33791/2222-4408-2024-4-264-271</mixed-citation><mixed-citation xml:lang="en">Kisele A.S., Maslova E.V., Trubilin A.V., Yavorovskaya A.A., Chernukha V.A. Dry eye syndrome associated with meibomian gland dysfunction due to isotretinoin therapy: clinical case. The EYE GLAZ. 2024; 26 (4): 264–72 (In Russ.). doi: 10.33791/2222-4408-2024-4-264-271</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Acar Eser N, Kocabeyoğlu S, Atakan N, Irkec M. The effects of systemic isotretinoin treatment on ocular surface and meibomian glands: a prospective longitudinal study. Cutan Ocul Toxicol. 2022 Jun; 41 (2): 155–61. doi: 10.1080/15569527.2022.2077749</mixed-citation><mixed-citation xml:lang="en">Acar Eser N, Kocabeyoğlu S, Atakan N, Irkec M. The effects of systemic isotretinoin treatment on ocular surface and meibomian glands: a prospective longitudinal study. Cutan Ocul Toxicol. 2022 Jun; 41 (2): 155–61. doi: 10.1080/15569527.2022.2077749</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Рикс И.А., Труфанов С.В., Боутаба Р. Современные подходы к лечению дисфункции мейбомиевых желез. Вестник офтальмологии. 2021; 137 (1): 130–6.</mixed-citation><mixed-citation xml:lang="en">Riks I.A., Trufanov S.V., Boutaba R. Modern approaches to treatment of meibomian gland dysfunction. Vestnik oftal’mologii. 2021; 137 (1): 130–6 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Moy A, McNamara NA, Lin MC. Effects of isotretinoin on meibomian glands. Optom Vis Sci. 2015 Sep; 92 (9): 925–30. doi: 10.1097/OPX.0000000000000656</mixed-citation><mixed-citation xml:lang="en">Moy A, McNamara NA, Lin MC. Effects of isotretinoin on meibomian glands. Optom Vis Sci. 2015 Sep; 92 (9): 925–30. doi: 10.1097/OPX.0000000000000656</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Elubous KA, Toubasi AA, Elubous A, Alryalat SA, Abous H. Ocular manifestations of systemic isotretinoin in patients with acne: a systematic review and meta-analysis. Cutan Ocul Toxicol. 2022 Jun; 41 (2): 113–22. doi: 10.1080/15569527.2022.2050747</mixed-citation><mixed-citation xml:lang="en">Elubous KA, Toubasi AA, Elubous A, Alryalat SA, Abous H. Ocular manifestations of systemic isotretinoin in patients with acne: a systematic review and meta-analysis. Cutan Ocul Toxicol. 2022 Jun; 41 (2): 113–22. doi: 10.1080/15569527.2022.2050747</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Медведев И.Б., Трубилин В.Н., Полунина Е.Г. и др. Современные возможности физиотерапевтического лечения дисфункции мейбомиевых желез. Офтальмология. 2022; 19 (2): 235–41. https://doi.org/10.18008/1816-5095-2022-2-235-241</mixed-citation><mixed-citation xml:lang="en">Medvedev I.B., Trubilin V.N., Polunina E.G., et al. Modern possibilities of physiotherapeutic treatment in meibomian gland dysfunction. Ophthalmology in Russia. 2022; 19 (2): 235–41 (In Russ.). https://doi.org/10.18008/1816-5095-2022-2-235-241</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин В.Н., Полунина Е.Г., Маркова Е.Ю. и др. Лечебная гигиена век в алгоритмах профилактики и лечения заболеваний глазной поверхности. Офтальмология. 2016; 13 (2): 122–7. https://doi.org/10.18008/1816-5095-2016-2-122-127</mixed-citation><mixed-citation xml:lang="en">Trubilin V.N., Polunina E.G., Markova E.Y., et al. Therapeutic eyelids hygiene in algorithms of prevention and treatment of ocular surface diseases. Ophthalmology in Russia. 2016; 13 (2): 122–7 (In Russ.). https://doi.org/10.18008/1816-5095-2016-2-122-127</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Майчук Д.Ю., Лошкарева А.О., Цветкова Т.В. Алгоритм комплексной терапии синдрома сухого глаза с дисфункцией мейбомиевых желез интенсивным импульсным светом (IPL) в сочетании с гигиеной век и слезозамещением. Офтальмология. 2020; 17 (3s): 640–7. https://doi.org/10.18008/1816-5095-2020-3s-640-647</mixed-citation><mixed-citation xml:lang="en">Maychuk D.Yu., Loshkareva A.O., Tsvetkova T.V. The Complex treatment algorithm for dry eye syndrome with meibomian gland dysfunction. Combination of intense pulsed light (IPL) with eyelid hygiene and artificial tears. Ophthalmology in Russia. 2020; 17 (3s): 640–7 (In Russ.). https://doi.org/10.18008/1816-5095-2020-3s-640-647</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Toyos R, Toyos M, Willcox J, Mulliniks H, Hoover J. Evaluation of the safety and efficacy of intense pulsed light treatment with meibomian gland expression of the upper eyelids for dry eye disease. Photobiomodul Photomed Laser Surg. 2019 Sep; 37 (9): 527–31. doi: 10.1089/photob.2018.4599</mixed-citation><mixed-citation xml:lang="en">Toyos R, Toyos M, Willcox J, Mulliniks H, Hoover J. Evaluation of the safety and efficacy of intense pulsed light treatment with meibomian gland expression of the upper eyelids for dry eye disease. Photobiomodul Photomed Laser Surg. 2019 Sep; 37 (9): 527–31. doi: 10.1089/photob.2018.4599</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017 Nov; 183: 81–90. doi: 10.1016/j.ajo.2017.08.021</mixed-citation><mixed-citation xml:lang="en">Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017 Nov; 183: 81–90. doi: 10.1016/j.ajo.2017.08.021</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kalil CLPV, Reinehr CPH, Milman LM. Intense pulsed light: review of clinical indications. Surg Cosmet Dermatol. 2017; 9 (1): 9–17. doi: 10.5935/scd1984-8773.201791967</mixed-citation><mixed-citation xml:lang="en">Kalil CLPV, Reinehr CPH, Milman LM. Intense pulsed light: review of clinical indications. Surg Cosmet Dermatol. 2017; 9 (1): 9–17. doi: 10.5935/scd1984-8773.201791967</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zemanova M, Macejova I, Svobodova I, Vlkova E. Treatment of mild forms of blepharitis using direct plasma discharge. Adv Ophthalmol Vis Syst. 2020; 10 (5): 397. doi: 10.15406/aovs.2020.10.00397</mixed-citation><mixed-citation xml:lang="en">Zemanova M, Macejova I, Svobodova I, Vlkova E. Treatment of mild forms of blepharitis using direct plasma discharge. Adv Ophthalmol Vis Syst. 2020; 10 (5): 397. doi: 10.15406/aovs.2020.10.00397</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
